Sender Co & Partners Inc. Acquires New Shares in Zoetis Inc. (NYSE:ZTS)

Sender Co & Partners Inc. purchased a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 8,501 shares of the company's stock, valued at approximately $1,385,000. Zoetis comprises 1.3% of Sender Co & Partners Inc.'s holdings, making the stock its 21st biggest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC increased its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 166 shares during the last quarter. Navigoe LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $30,000. Murphy & Mullick Capital Management Corp bought a new stake in shares of Zoetis in the 4th quarter valued at about $44,000. Finally, Asset Planning Inc bought a new stake in shares of Zoetis in the 4th quarter valued at about $58,000. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on ZTS shares. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler upped their price target on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Stifel Nicolaus reduced their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Finally, Barclays upped their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $212.75.

Insider Activity at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02% decrease in their position. The disclosure for this sale can be found here. 0.18% of the stock is owned by company insiders.

Zoetis Stock Down 0.2%

Shares of Zoetis stock traded down $0.31 on Tuesday, reaching $163.63. 1,780,660 shares of the company were exchanged, compared to its average volume of 2,512,361. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a market capitalization of $72.85 billion, a price-to-earnings ratio of 29.91, a PEG ratio of 2.78 and a beta of 0.94. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a 50-day moving average of $156.51 and a 200 day moving average of $165.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter in the prior year, the business earned $1.38 EPS. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.